Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

Circulation. 2003 Jun 3;107(21):2747-52. doi: 10.1161/01.CIR.0000066912.58385.DE. Epub 2003 May 12.

Abstract

Background: Nebivolol and carvedilol are third-generation beta-adrenoreceptor antagonists, which unlike classic beta-blockers, have additional endothelium-dependent vasodilating properties specifically related to microcirculation by a molecular mechanism that still remains unclear. We hypothesized that nebivolol and carvedilol stimulate NO release from microvascular endothelial cells by extracellular ATP, which is a well-established potent autocrine and paracrine signaling factor modulating a variety of cellular functions through the activation of P2-purinoceptors.

Methods and results: Contraction and relaxation of renal glomerular vasculature were measured by determination of intracapillary volume with [3H]-inulin. Biologically active NO was measured with highly sensitive porphyrinic NO microsensors in a single glomerular endothelial cell (GEC). Extracellular ATP was measured by a luciferin-luciferase assay. Enzymatic degradation of extracellular ATP by apyrase and blockade of P2Y-purinoceptors by suramin or reactive blue 2 inhibited both beta-blocker-induced glomerular vasorelaxations and beta-blocker-stimulated NO release from GECs. Both beta-blocker-induced vasorelaxations were in the micromolar concentration range identical to that required for the beta-blocker stimulation of ATP and NO release from GECs. The maximum of NO release for nebivolol and carvedilol was very similar (188+/-14 and 226+/-17, respectively). Blockade of ATP release by a mechanosensitive ion channel blocker, Gd3+, inhibited the beta-blocker-dependent release of ATP and NO from GECs.

Conclusions: These results demonstrate for the first time that nebivolol and carvedilol induce relaxation of renal glomerular microvasculature through ATP efflux with consequent stimulation of P2Y-purinoceptor-mediated NO release from GECs.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine Triphosphate / metabolism*
  • Adrenergic beta-Antagonists / pharmacology*
  • Angiotensin II / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Benzopyrans / pharmacology
  • Carbazoles / pharmacology
  • Carvedilol
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism*
  • Ethanolamines / pharmacology
  • Extracellular Space / metabolism
  • Gadolinium / pharmacology
  • Intracellular Fluid / metabolism
  • Kidney Glomerulus / blood supply
  • Kidney Glomerulus / cytology
  • Luminescent Measurements
  • Male
  • Microcirculation / cytology
  • Microcirculation / physiology
  • Nebivolol
  • Nitric Oxide / metabolism*
  • Propanolamines / pharmacology
  • Rats
  • Receptors, Purinergic P2
  • Suramin / pharmacology
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology
  • Vasodilation / drug effects
  • Vasodilation / physiology

Substances

  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Benzopyrans
  • Carbazoles
  • Ethanolamines
  • Propanolamines
  • Receptors, Purinergic P2
  • Nebivolol
  • Carvedilol
  • Angiotensin II
  • Nitric Oxide
  • Suramin
  • Adenosine Triphosphate
  • Gadolinium